TALICIA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TALICIA (TALICIA).
TALICIA (amoxicillin, clarithromycin, and omeprazole) is a combination product for Helicobacter pylori eradication. Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis. Clarithromycin binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis. Omeprazole is a proton pump inhibitor (PPI) that irreversibly inhibits the gastric H+/K+-ATPase, reducing gastric acid secretion and increasing antibiotic stability and efficacy.
| Metabolism | Amoxicillin is partially metabolized by hepatic hydrolysis to inactive penicilloic acid; clarithromycin is primarily metabolized by CYP3A4 to active 14-hydroxyclarithromycin; omeprazole is extensively metabolized by CYP2C19 and CYP3A4 to inactive metabolites. |
| Excretion | Renal: 30% unchanged; fecal/biliary: 70% (primarily as metabolites) |
| Half-life | Terminal elimination half-life is 4-6 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 20-30% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein). |
| Volume of Distribution | 0.8-1.2 L/kg, indicating distribution into total body water and tissues. |
| Bioavailability | Oral: 85-95%. |
| Onset of Action | Oral: 1-2 hours; IV: within 30 minutes. |
| Duration of Action | 12 hours for antimicrobial effect; dosing interval is typically 12 hours. |
2 tablets orally twice daily (each tablet contains 3 g amoxicillin, 250 mg metronidazole, and 500 mg omeprazole); total daily dose: 6 g amoxicillin, 500 mg metronidazole, 1 g omeprazole for 10 days.
| Dosage form | CAPSULE, DELAYED RELEASE |
| Renal impairment | Contraindicated if CrCl < 30 mL/min. For CrCl 30-60 mL/min: no adjustment needed. For CrCl < 30 mL/min: do not use. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh C). For Child-Pugh A or B: caution; monitor for metronidazole toxicity. |
| Pediatric use | Not approved for pediatric patients (<18 years). No established dosing. |
| Geriatric use | No specific dose adjustment recommended; use caution due to increased risk of renal impairment and electrolyte disturbances from omeprazole. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TALICIA (TALICIA).
| Breastfeeding | Omadacycline is excreted in human milk; M/P ratio not reported. Tetracyclines can cause permanent tooth discoloration and bone growth inhibition in nursing infants. Breastfeeding is not recommended during therapy and for 4-5 days after last dose (approx 5 half-lives). |
| Teratogenic Risk | TALICIA contains omadacycline, a tetracycline-class antibiotic. Tetracyclines are associated with fetal risk including bone growth retardation and dental discoloration (enamel hypoplasia) when used during second and third trimesters. Safety in first trimester has not been established; animal studies show embryo-fetal toxicity. Use is contraindicated in pregnancy unless no alternative. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any component (amoxicillin, clarithromycin, omeprazole) or other beta-lactams, macrolides, or PPIs; history of cholestatic jaundice/hepatic dysfunction with clarithromycin; concurrent use with ticagrelor, ranolazine, ergot alkaloids, or colchicine (in renal/hepatic impairment); concurrent use with cisapride, pimozide, or HMG-CoA reductase inhibitors metabolized by CYP3A4 (e.g., lovastatin, simvastatin); history of QT prolongation or torsades de pointes; severe renal impairment (CrCl <30 mL/min) without dose adjustment; known phenylketonuria (product contains aspartame).
| Precautions | Clostridium difficile-associated diarrhea; hypersensitivity reactions including anaphylaxis; prolonged QT interval with clarithromycin (avoid in patients with known QT prolongation or electrolyte disturbances); hepatotoxicity; renal impairment (adjust dose for CrCl <30 mL/min); exacerbation of myasthenia gravis; interference with INR if on warfarin; Clostridium difficile-associated diarrhea; Stevens-Johnson syndrome; acute interstitial nephritis; hematologic toxicity; optic neuritis with clarithromycin; drug interactions (e.g., statins, colchicine, digoxin) due to CYP3A4 inhibition by clarithromycin; increased gastric carcinoid risk with long-term PPI use; vitamin B12 deficiency with long-term PPI use; osteoporosis-related fractures with long-term PPI use; hypomagnesemia with PPI use; interaction with methotrexate. |
Loading safety data…
| Fetal Monitoring | Monitor liver function tests (AST, ALT), renal function, and complete blood count periodically. In pregnancy, monitor fetal growth and development via ultrasound if exposure occurs. Watch for signs of superinfection or Clostridioides difficile diarrhea. |
| Fertility Effects | Tetracyclines can reduce fertility in animal studies via effects on spermatogenesis and oocyte maturation. Human data lacking; advise caution in patients planning conception. |